MS Speaks

From The Lancet Neurology (March 12, 2018).This study was funded by Biogen. It shows that Tysabri didn't change the EDSS score for persons with SPMS but did improve arm functioning somewhat, using the 9-hole peg test:

No treatment effect was observed on the EDSS (OR 1·06, 95% CI 0·74–1·53; nominal p=0·753) or the T25FW (0·98, 0·74–1·30; nominal p=0·914) components of the primary outcome. However, natalizumab treatment reduced 9HPT [9-hole peg test] progression (OR 0·56, 95% CI 0·40–0·80; nominal p=0·001). In part 1, 100 (22%) placebo-treated and 90 (20%) natalizumab-treated patients had serious adverse events. In part 2, 291 natalizumab-continuing patients and 274 natalizumab-naive patients received natalizumab (median follow-up 160 weeks [range 108–221]). Serious adverse events occurred in 39 (13%) patients continuing natalizumab and in 24 (9%) patients initiating natalizumab.

http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(18)30069-3/fulltext